Panacos Pharmaceuticals, Inc.
Other OTCTotal Valuation
Panacos Pharmaceuticals, Inc. carries a market capitalization of 5,367.00, placing it among publicly traded companies globally. Its enterprise value stands at -7.05M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5,367.00 |
| Enterprise Value | -7.05M |
Share Statistics
Panacos Pharmaceuticals, Inc. currently has 53.64M shares outstanding.
| Shares Outstanding | 53.64M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 16.51, and the price-to-book ratio stands at -0.01.
| PE Ratio | N/A |
| PS Ratio | 16.51 |
| PB Ratio | -0.01 |
| P/TBV Ratio | 0.31 |
| P/FCF Ratio | -0.05 |
| P/OCF Ratio | -0.05 |
Enterprise Valuation
| EV / Sales | 218.11 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Panacos Pharmaceuticals, Inc. maintains a current ratio of 2.15, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.15 |
| Quick Ratio | 2.11 |
| Debt / Equity | 345.33 |
| Debt / EBITDA | -0.55 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -87.96 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Panacos Pharmaceuticals, Inc.'s stock has gained approximately 0.000003% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.000003% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Panacos Pharmaceuticals, Inc. generated 99,000.00 in revenue and converted that into -35.75M in net income, yielding earnings per share of -0.67. EBITDA reached -33.00M, while operating income came in at -34.22M.
| Revenue | 99,000.00 |
| Gross Profit | N/A |
| Operating Income | -34.22M |
| Pretax Income | N/A |
| Net Income | -35.75M |
| EBITDA | -33.00M |
| EBIT | -34.22M |
| Earnings Per Share (EPS) | -0.67 |
Balance Sheet
Panacos Pharmaceuticals, Inc. holds 26.89M in cash and equivalents against 18.21M in total debt, resulting in a net debt position of -3.22M. Total book value stands at -185.89M, with working capital of 14.70M providing operational flexibility.
| Cash & Cash Equivalents | 26.89M |
| Total Debt | 18.21M |
| Net Debt | -3.22M |
| Equity (Book Value) | -185.89M |
| Book Value Per Share | -3.47 |
| Working Capital | 14.70M |
Cash Flow
Panacos Pharmaceuticals, Inc. produced -31.15M in operating cash flow over the past twelve months. After subtracting -96,000.00 in capital expenditures, free cash flow totaled -31.24M - equivalent to -0.58 per share.
| Operating Cash Flow | -31.15M |
| Capital Expenditures | -96,000.00 |
| Free Cash Flow | -31.24M |
| FCF Per Share | -0.58 |
Margins
Panacos Pharmaceuticals, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -34,568.69 and net profit margin of -36,116.16 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -34,568.69 |
| Pretax Margin | N/A |
| Profit Margin | -36,116.16 |
| EBITDA Margin | -33,333.33 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -539.01 |
| FCF Yield | -1,899.75 |
Stock Splits
Panacos Pharmaceuticals, Inc.'s most recent stock split took place on March 15, 2005 with a 10:1 split ratio.
| Last Split Date | 3/15/2005 |
| Split Ratio | 10:1 |
Scores
Panacos Pharmaceuticals, Inc. posts an Altman Z-Score of -11.94, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -11.94 |